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Abstract
MIA/CD-RAP is a small, secreted protein involved in cartilage differentiation and melanoma progression. We recently
revealed that p54nrb acts as a mediator of MIA/CD-RAP action to promote chondrogenesis and the progression of malignant
melanoma. As the molecular mechanism of MIA/CD-RAP action in cartilage has not been defined in detail until now, we
aimed to understand the regulation of p54nrb transcription in chondrogenesis. We concentrated on the previously described
MIA/CD-RAP-dependent regulatory region in the p54nrb promoter and characterized the transcriptional regulation of p54nrb
by MIA/CD-RAP in cartilage. A series of truncated p54nrb promoter constructs and mutagenesis analysis revealed that the
transcription factor YBX1, which has not been investigated in chondrogenesis thus far, is the mediator of MIA/CD-RAP
dependent activation of p54nrb transcription. A systematic analysis of genes carrying this binding site in their promoter
region revealed further potential MIA/CD-RAP-regulated genes that have been implicated in cartilage differentiation. In
summary, we described the effects of MIA/CD-RAP on transcriptional regulation in chondrocytes. Understanding the
regulation of p54nrb via YBX1 contributes to the understanding of chondrogenesis. Uncovering new downstream effectors
that function via the activation of YBX1 supports the important role of MIA/CD-RAP in these processes.
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Introduction
Melanoma inhibitory activity (MIA)/cartilage-derived retinoic
acid-sensitive protein (CD-RAP) is secreted from malignant
melanoma cells [1,2] as well as chondrocytes [3]. Developmental
expression analysis by in situ hybridization of mouse embryos
shows that MIA/CD-RAP expression is initiated at the beginning
of chondrogenesis and is subsequently restricted to cartilage tissue,
in which MIA/CD-RAP expression remains abundant throughout
development [4,3]. MIA/CD-RAP expression is tightly correlated
to the expression of cartilage specific type II collagen [4] and to the
expression of the chondrogenic differentiation marker aggrecan
during cartilage development [5]. Analysis of the role of MIA/
CD-RAP during cartilage development revealed that MIA/CD-
RAP by itself is not capable to induce the differentiation of
mesenchymal stem cells. However, together with bone morpho-
genetic protein (BMP)-2 and transforming growth factor (TGF)-
b3, MIA/CD-RAP enhances the chondrogenic phenotype while
inhibiting osteogenic differentiation during mesenchymal stem cell
differentiation [6].
Recent expression analysis in cartilage tissue derived from
MIA/CD-RAP-deficient mice revealed a strong down-regulation
of p54nrb (non-POU-domain-containing octamer-binding protein)
[7]. The p54nrb protein was first isolated from the cervical cell line
HeLa [8] and has nucleic acid binding abilities that enable its dual
roles in transcription and splicing [8,9]. It is known that p54nrb
retains messenger RNAs in the nucleus and therefore influences
gene expression [10]. In chondrogenesis, p54nrb interacts with the
transcription factor Sox9 and enhances the Sox9-mediated
activation of the Col2a1 promoter promoting chondrogenesis
[11]. We were able to show that p54nrb acts as a mediator of MIA/
CD-RAP action to promote chondrogenesis through the inhibition
of proliferation by negative cell cycle regulation via Cyclin D2 and
through the induction of differentiation via enhanced Sox9-
dependent COL2A1 promoter activity [7].
We also found strongly down-regulated p54nrb protein levels [7]
and decreased p54nrb promoter activity [12] in a previously
described MIA-deficient HMB2 melanoma cell system [13,14]. As
an MIA/CD-RAP target molecule, p54nrb is involved in the
development and progression of malignant melanoma [12].
Because melanoma cell lines have been shown to have strong
p54nrb promoter activity, the regulation of p54nrb via MIA/CD-
RAP was shown to involve transcriptional regulation. Recently, we
identified one highly conserved region in the p54nrb promoter that
is necessary for MIA-dependent activation in melanoma [15].
Additionally, we defined the transcription factor Y-box binding
protein 1 (YBX1) as the mediator of MIA/CD-RAP dependent
p54nrb transcription [15]. YBX1 is a multifunctional protein,
which regulates transcription through binding to promoters
containing the Y-box motif (inverted CCAAT-Box) [16,17] and
inhibits translation through masking of mRNA or regulation of
mRNA stability [18,19]. In vivo YBX1 is expressed throughout
embryonal development and its expression correlates with cell
proliferation [20]. The majority of YBX1-knockout embryos
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develop normally until day 13.5 of development. Afterwards
severe growth retardation and mortality was observed, uncovering
a nonredundant role of YBX1 in late stages of embryonic
development [21].
The aim of this study was to characterize the transcriptional
regulation of p54nrb by MIA/CD-RAP during cartilage develop-
ment to explain the action of MIA/CD-RAP during this process.
To examine p54nrb transcription during chondrogenesis, we used
primary murine mesenchymal stem cells isolated from MIA/CD-
RAP-deficient mice and analyzed the already known highly
conserved MIA/CD-RAP-regulated p54nrb promoter region.
Materials and Methods
Animals
Transgenic mice were generated as previously described [22].
C57Bl/6 control and MIA/CD-RAP knockout mice were bred
under specified pathogen-free conditions at 26uC and 70% relative
humidity and were kept under a 12 hour light/12 hour dark cycle
at the University of Regensburg. They were fed a breeding/
maintenance diet (Altromin GmbH, Lage, Germany) and given
water ad libitum. The mice were randomly housed in polypropylene
cages with sawdust bedding. The cages were sanitized twice each
week. Animal care and all experimental procedures were carried
out in accordance with the guidelines of the German law
governing animal care and use in biomedical research. All efforts
were made to minimize the number of animals used and their
suffering. Adult mice were sacrificed via cervical dislocation after
anesthetization by isoflurane (2-chloro-2-(difluoromethoxy)-1,1,
1-trifluoro-ethane) inhalation. According to the German Animal
Welfare Act 2006 (article 4), it is sufficient to obtain supervision
from the local animal welfare officer (Dr. Thilo Spruss, University
Hospital Regensburg) for the killing of mice for scientific purposes
(including tissue, embryo and cell extraction) if no experimental
procedures were carried out in the animals. As this was the case in
this study, no further notification or approval by the Ethics
Committee for Animal Research of the Bavarian government was
necessary.
Human tissue samples
The sampling and handling of human tissue was carried out in
accordance with the ethical principles of the Declaration of
Helsinki and was approved by the ethical committee of the
University of Regensburg. As no information about the patients
was used, other than the type of tumor, no written informed
consent for the use of the samples in research was deemed
necessary by the ethical committee.
Cell isolation and cell culture of primary murine
mesenchymal stem cells (mMSCs)
Murine MSCs were isolated and cultured as previously
described [7]. All experiments were performed in cells between
passages three and six.
Differentiation
The differentiation of mMSCs was performed in two-dimen-
sional (2D) cultures. For this procedure, the cells were cultured in
induction medium including DMEM (PAA Laboratories Inc.,
Dartmouth, NH, USA), 0.3% glucose (Sigma-Aldrich Corp., St.
Louis, MO, USA), 0.4% MEM vitamins (Life Technologies Inc.,
Carlsbad, CA, USA), 100 U/ml penicillin, 100 mg/ml streptomy-
cin (both PAA), 500 ng/ml amphotericin-B, 0.1 mM dexametha-
sone, 1 mM sodium pyruvate, 0.17 mM ascorbic acid-2-phos-
phate, 0.35 mM proline (all Sigma), 5 mg/ml insulin, 5 mg
transferrin, 5 ng selenous acid (ITSTM Premix; Becton Dickinson
Biosciences, San Jose, CA, USA) and 10 ng/mL human TGF-b3
(HumanZyme Inc., Chicago, IL, USA). Each experiment was
conducted with at least three different lots of cells. Cells were
harvested for isolation of RNA and protein.
Luciferase assay
For transient transfections, 1 – 1.56105 mMSCs (per well) were
seeded into 6-well plates and transfected with 0.5 mg of plasmid
DNA using the Lipofectamine Plus method (Life Technologies
Inc.) according to the manufacturer’s instructions. Murine MSCs
were cultured in induction medium (see above) containing 10 ng/
mL human TGF-b3 (HumanZyme Inc.) to induce chondrogenic
differentiation. The cells were lysed 24 h after transfection, and
the luciferase activity in the lysate was quantified with a
luminometer using the Dual-Luciferase Reporter Assay System
(Promega, Mannheim, Germany). Transfection efficiency was
normalized according to the Renilla luciferase activity produced by
cotransfection of 0.1 mg of the pRL-TK plasmid (Promega). Basal
activity resulting from the pGL3basic or pGL4.10[luc2] vector was
set to 1. All transfections were repeated at least twice.
Luciferase reporter constructs
For transient transfection, the YBX1 promoter reporter
construct (YBX1Luc) was kindly provided by Per S. Holm [23].
The YBX1 II reporter construct (YBX1Luc II) was kindly
provided by Kiyoshi Higashi. Four copies of the Y-box consensus
oligo (CTGATTGGCTAA) linked to a minimal promoter
containing only a TATA box were cloned into the pGL3basic
vector [24]. The human (hp54nrbLuc) and mouse (mp54nrbLuc)
p54nrb promoter reporter constructs, as well as the respective
mutated and deleted hp54nrbLuc fragments, were used as
previously described [15]. The human p54nrb construct spans from
28436 to 26833 bp, and the mouse p54nrb construct spans from
29160 to 27461 bp, with the numbering of each fragment
relative to the translation start site of the gene.
siRNA transfection
The siRNAs against mouse MIA/CD-RAP (Mm_MIA 20-43;
see Table 1 for all sequences) were purchased from Sigma. Control
siRNA was synthesized by Qiagen (Hilden, Germany). One day
after seeding mMSCs into 6-well plates (16105 per well), the cells
were transfected with siRNA using the Lipofectamine 2000
reagent (Life Technologies Inc.) according to the manufacturer’s
specifications. One day after siRNA transfection, the cells were
transiently transfected with plasmid DNA for the luciferase assay
as described above. The knockdown efficiency was assessed using
quantitative real-time PCR (see below).
RNA isolation and reverse transcription-PCR
Total RNA was isolated from cultured cells using the e.Z.N.A. H
MicroEluteH Total RNA Kit (Omega Bio-Tek, Norcross, GA,
USA) according to the manufacturer’s protocol. RNA concentra-
tion and purity was measured using a NanoDrop spectrophotom-
eter (peqlab Biotechnologie GmbH, Erlangen, Germany). Com-
plementary DNA (cDNA) was generated by the reverse
transcription of 500 ng of total RNA as previously described [12].
Quantitative Real-Time PCR (qRT-PCR)
Quantitative RT-PCR analysis of murine MIA/CD-RAP and
Gnas mRNA expression was performed using a LightCyclerH 480
system (Roche, Mannheim, Germany) as described elsewhere [25].
The primers used for PCR were obtained from Sigma and are
YBX1 in Chondrogenesis
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shown in Table 2. Each analysis was performed in at least
duplicate. The expression ratios of the analyzed genes were
calculated using an internal control and a standard curve of b-
actin levels.
Western blot analysis
Western blot analysis was performed as previously described
[12]. After blotting onto PVDF membranes (Bio-Rad, Richmond,
CA, USA) and blocking for 1 h with 3% BSA/PBS (p54nrb) or 5%
milk/TBST (0.1%) (phospho-YBX1), the membranes were
incubated with one of the following antibodies: anti-p54nrb
(1:2000; BD Biosciences, Bedford, MA, USA), anti-phospho-YB1
(Ser102) (1:500; #2900, Cell Signaling, Danvers, MA, USA) or
anti-b-actin (Sigma).
Preparation of nuclear extracts
Nuclear extracts were prepared from cultured cells using the
method described by Dignam et al. [26]. For the isolation of
nuclear extracts, murine mesenchymal stem cells were harvested
after differentiation in induction medium (see above).
Electrophoretic Mobility Shift Assay (EMSA)
Double-stranded DNA oligos corresponding to the sequences
of the MIA/CD-RAP-dependent human p54nrb promoter region
(59- and 39-hp54nrb, Table 1) and two double-stranded mutated
DNA oligos corresponding to the 59-hp54nrb region (59-hp54nrb
Mut I and 59-hp54nrb Mut II, Table 1) were synthesized by
Sigma. The fragments correspond to the human p54nrb promoter
regions from -7079 to -7062 (59-hp54nrb) and from -7061 to -7038
(39-hp54nrb) upstream of the ATG start site. The fragments were
end labeled, and the EMSA assay was performed as previously
described [27].
Immunohistochemical staining
Paraffin sections of human and mouse cartilage tissues were
screened for YBX1 protein expression by immunohistochemistry.
Formalin-fixed and paraffin-embedded tissues were deparaffi-
nized, rehydrated, heat treated with Tris–EDTA and subsequently
incubated with primary YBX1 antibody (1:20; #4202, Cell
Signaling) for 30 min at room temperature. The sections were
incubated with secondary antibody (human: Labeled Polymer,
HRP - EnVision+; Dako, Carpinteria, CA, USA; mouse: Labeled
Polymer, HRP - Histofine anti-rabbit; Nichirei Biosciences Inc.,
Tokyo, Japan) for 30 min at room temperature. Antibody binding
was visualized using DAB+Substrate Chromogen solution (Dako).
Finally, the tissues were counterstained with hematoxylin (Merck,
Darmstadt, Germany).
Bioinformatics analysis
HGU133PUS2 chip data, which were previously normalized by
Dehne et al. (GSE16464), were used to identify differentially
expressed genes between differentiated and undifferentiated
chondrocytes. In total, 175 genes sharing the motif GATTGG
in their promoter region were tested using a paired Student’s t-test;
62 differentially expressed genes were identified (adjusted p value
,0.05, Benjamini-Hochberg correction).
Statistical analysis
The mean and standard deviation values were calculated from
the independent experiments. Graphs were prepared using the
GraphPad PrismH 4.03 software (GraphPad Software Inc., San
Diego, CA, USA). Statistical significance between two groups was
determined using Student’s t-test in GraphPad Prism 4. Statistical
significance was determined using data from at least three
independent experiments. A p-value ,0.05 was considered
statistically significant and marked with an asterisk (ns: not
significant, *p,0.05; **p,0.01; ***p,0.001).
Results
We previously showed that p54nrb acts as a mediator of MIA/
CD-RAP action during cartilage development to promote
chondrogenesis [7] and that there was evidence of transcriptional
regulation of p54nrb expression [12]. To analyze the regulatory
mechanism underlying the regulation of the p54nrb gene by MIA/
CD-RAP in chondrocytes, we analyzed a highly conserved region
of the p54nrb promoter.
Table 1. Oligonucleotides used in the study as indicated in
Material and Methods.
Name Sequence









59-hp54nrb Mut I (EMSA) 59-TCTGGCCTTGATATCCAGTTTAG-39
59-hp54nrb Mut II (EMSA) 59-TCTGGCCTTCCATGGCAGTTTAG-39
doi:10.1371/journal.pone.0082166.t001
Table 2. Primers used for quantitative real-time PCR (qRT-PCR).
Gene Species Sequence (forward/reverse) Product size [bp] NCBI reference sequence
Actb mouse 59-TGGAATCCTGTGGCATCCATGAAAC-39 320 NM_007393
59-TAAAACGCAGCTCAGTAACAGTCCG-39
Gnas mouse 59-GCAGAAGGACAAGCAGGTCT-39 126 NM_201616
59-CCCTCTCCGTTAAACCCATT-39
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p54nrb promoter regulation is MIA/CD-RAP dependent
The activities of the mouse and human p54nrb promoters and the
influence of MIA/CD-RAP were analyzed using luciferase repor-
ter assays. Luciferase measurement after transient transfection of
the murine p54nrb (mp54nrb) promoter construct into differentiated
primary murine mesenchymal stem cells (mMSCs) revealed strong
activity in the MIA/CD-RAP wild type cells and a marked redu-
ction in mMSCs derived from the MIA/CD-RAP-deficient
(MIA-/-) mice (Figure 1A). Diminished mp54nrb promoter activity
in the wild-type (WT) mMSCs treated with siRNA specific to
MIA/CD-RAP confirmed these data (Figure 1B). The knockdown
efficiency of MIA/CD-RAP in the WT mMSCs was confirmed
using quantitative real-time PCR (qRT-PCR) (Figure 1C).
Transient transfection of the hp54nrb promoter construct into
murine MSCs also resulted in strong activity, whereas the
transcriptional activity was reduced in MIA-/- mMSCs
Figure 1. p54nrb promoter activity is controlled by MIA/CD-RAP. (A) Luciferase reporter assays revealed strong activity of the murine p54nrb
(mp54nrb) promoter in primary murine mesenchymal stem cells (mMSCs). In MIA/CD-RAP-deficient (MIA-/-) mMSCs, the promoter activity was
reduced (***p,0.001). The values represent the mean6 s.d. from four independent experiments. (B) Murine p54nrb promoter activity analyzed using
reporter gene assays was decreased in the wild-type (WT) mMSCs transfected with siRNA against MIA/CD-RAP compared with the control (*p,0.05).
The values represent the mean 6 s.d. from three experiments. (C) The knockdown efficiency of MIA/CD-RAP in WT mMSCs was validated using qRT-
PCR. The MIA/CD-RAP mRNA expression was successfully inhibited compared to the siControl-transfected cells (*p,0.05). The values represent the
mean 6 s.d. from three independent experiments. (D) The human p54nrb promoter analyzed using reporter gene assays was highly active in WT
mMSCs and showed reduced activity in MIA-/- mMSCs (***p,0.001). The values represent the mean 6 s.d. from eleven experiments.
doi:10.1371/journal.pone.0082166.g001
Figure 2. Mapping the p54nrb promoter region that mediates the effects of MIA/CD-RAP on p54nrb transcription. The human p54nrb
promoter luciferase constructs ranging from residues 28436 to 27037 bp are indicated on the left. The luciferase activities resulting from transient
transfections into WT (white bars) or MIA-/- mMSCs (black bars) are indicated in the middle. The ratios of human p54nrb promoter activities comparing
WT and MIA-/- mMSCs are shown on the right for each luciferase construct. The ratio of the human p54nrb promoter activity comparing WT and MIA-/-
mMSCs significantly decreased in deletions involving the region between 27079 and 27037 bp, identifying this 42 bp DNA region as the mediator
of MIA/CD-RAP up-regulation of p54nrb promoter activity (*p,0.05). The values represent the mean 6 s.d. from three experiments.
doi:10.1371/journal.pone.0082166.g002
YBX1 in Chondrogenesis
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(Figure 1D). In conclusion, the human and murine p54nrb
promoter constructs were strongly conserved, and both were
functional in the mouse systems. Importantly, their activity was
modulated by MIA/CD-RAP.
MIA dependency is linked to a 42 bp DNA element in the
p54nrb promoter
Based on a previous study in melanoma [15], we investigated a
series of truncated p54nrb promoter-luciferase constructs. The
defined human p54nrb-luciferase constructs were transfected into
primary WT and MIA-/- mMSCs (Figure 2). Figure 2 shows a
summary of the promoter constructs on the left and the resulting
promoter activities in the center. On the right, the ratio comparing
the WT and MIA-/- promoter activity is depicted, illustrating the
influence of MIA/CD-RAP when the ratio is significantly higher
than 1. We revealed that the promoter region between27079 and
27037 bp is necessary and sufficient for MIA/CD-RAP to
increase the p54nrb promoter activity in mesenchymal stem cells.
In summary, these assays led to the conclusion that the 42 bp
DNA element between 27079 and 27037 bp in the p54nrb
promoter is highly conserved and mediates MIA/CD-RAP-
induced gene transcription during chondrogenesis.
Figure 3. EMSA competition experiments and reporter gene assays demonstrated binding ability to one specific region in the
p54nrb promoter. (A) Schematic overview of the MIA/CD-RAP-dependent region between 27079 and 27038 bp, highlighted in grey, of the human
p54nrb promoter-luciferase reporter. The oligos used for the EMSA assay were labeled as follows: 59-, 39-hp54nrb and 59-hp54nrb Mut I and II. The
mutated regions are shown in bold letters. The numbers represent the locations with respect to the ATG translation start codon. (B) EMSA analysis
revealed two strong DNA-protein complexes interacting with the 59-hp54nrb oligo in the nuclear extracts from mMSCs (lane 3). Binding capacity of
MIA-/- mMSC (lane 4) nuclear extracts was diminished. No binding was observed with the 39-hp54nrb oligo (lane 5 and 6). (C) Incubation of nuclear
extracts from WT mMSCs (lane 4) with the 59-hp54nrb oligo confirmed the formation of two strong DNA-protein complexes that were diminished
when incubated with MIA-/- mMSC nuclear extracts (lane 7). Mutations I and II in the 59-hp54nrb oligo abolished the formation of DNA-protein
complexes in the nuclear extracts from WT cells and MIA-/- mMSCs (lane 5, 6 and 8, 9). The contents of the reaction mixtures are marked in the tables
below the images of the gels. (D) For competition experiments, the gel shifts were assessed in competition mixtures containing three different
concentrations (x-fold) of unlabeled 59-hp54nrb oligo (lanes 3–5) or unlabeled mutated oligos (Mut I and II) (lanes 6–8 and 9–11, respectively). In
contrast to incubation with unlabeled 59-hp54nrb oligo, incubation with the unlabeled mutated oligos did not lead to competition of the complexes
formed by the binding of the labeled 59-hp54nrb oligo to WT mMSC nuclear extracts (lane 2). (E) On the left, human p54nrb promoter-luciferase
constructs ranging from residues 27079 to 27037 are shown. Luciferase activities resulting from transient transfections are presented in the center.
The ratios of human p54nrb promoter activities in the WT and MIA-/- mMSCs are shown to the right of each luciferase construct. Mutation of site I or II
in the p54nrb promoter significantly abolished the MIA/CD-RAP-mediated p54nrb promoter activation as measured using the reporter gene assay
(*p,0.05; **p,0.01). The values represent the mean 6 s.d. from three independent experiments each.
doi:10.1371/journal.pone.0082166.g003
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Figure 4. MIA/CD-RAP activates the p54nrb promoter via the transcription factor YBX1. (A) YBX1 activity as measured using a reporter
gene assay revealed a significant decrease in YBX1 promoter activity in MIA-/- mMSCs compared with WT mMSCs (III) (**p,0.01). The values
represent the mean6 s.d. from eight independent experiments. (B) Luciferase reporter assays revealed the significant inhibition of YBX1Luc II activity
in MIA-/- mMSCs compared with WT mMSCs (**p,0.01). The values represent the mean 6 s.d. from four experiments. (C) Detection of p54nrb and
phospho-S102 YBX1 protein levels in WT and MIA-/- mMSCs analyzed by western blot analysis. Consistent with the reduced p54nrb protein levels, the
levels of phospho-S102 YBX1 were also considerably reduced in the MIA/CD-RAP-negative cell system compared with the control. (D) Western blot
analysis revealed elevated phospho-S102 YBX1 protein levels during differentiation of WT mMSC. (E) Immunohistochemical staining of YBX1 in rips of
YBX1 in Chondrogenesis
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Identification of transcription factor binding sites in the
p54nrb promoter
Putative transcription factor binding sites within the genomic
region between 27079 and 27037 bp of the human p54nrb
promoter (Figure 3A) were defined using the Gene2Promoter
program (www.genomatix.de). Two double-stranded oligomeric
fragments corresponding to 18 bp of the 59 region and to 24 bp of
the 39 region of the 42 bp DNA element (59- and 39-hp54nrb,
Figure 3A) were used in the electrophoretic mobility shift assays
(EMSA). We noted two strong DNA-protein complexes involving
the 59-hp54nrb oligo using nuclear extracts from primary mMSCs;
these complexes were reduced in the nuclear extracts from MIA-/-
mMSCs (Figure 3B). Nuclear extracts from WT mMSCs showed
no differential binding to the 39-hp54nrb oligo compared to the
respective MIA-negative cells (Figure 3B). Using the MatInspector
program (www.genomatix.de), we analyzed the genomic region
between 27079 and 27037 bp to determine the locations of the
specific regulatory elements. This analysis revealed two potential
binding sites for several transcription factors located between
27075 and 27070 bp. We designed two double-stranded
oligomeric fragments in which the first or the second binding site
in this region was mutated (59-hp54nrb Mut I and II). The
formation of a strong DNA-protein complex using nuclear extracts
from WT mMSCs was observed in gel mobility shift assays, and
these complexes were diminished when incubated with MIA-/-
mMSC nuclear extracts (Figure 3C). Mutations of the transcrip-
tion factor binding sites (59-hp54nrb Mut I and -II) nearly abolished
the formation of these DNA-protein complexes (Figure 3C).
To confirm the binding of WT mMSC nuclear extracts to the
59-hp54nrb oligo, we performed competition experiments using
three different ratios of unlabeled 59-hp54nrb, -Mut I and -Mut II
oligos in excess. Interestingly, even small amounts of unlabeled 59-
hp54nrb oligo eliminated the DNA-protein interaction between the
WT mMSC nuclear extracts and the 59-hp54nrb oligo. Further-
more, incubation with even the highest fold excess of unlabeled
Mut I or Mut II oligo resulted in no reduction in complex
formation between the WT mMSC nuclear extract and the 59-
hp54nrb oligo, thus suggesting these oligos could not compete for
binding (Figure 3D).
Next, we investigated the promoter activity of the 27079 to
26833 bp p54nrb promoter construct containing mutations I and
II. The transfection of these mutated p54nrb promoter constructs
into primary mMSCs revealed that both mutations led to an
almost complete loss of MIA/CD-RAP-dependent p54nrb promot-
er activity, as measured by the reporter gene assay (Figure 3E,
right graph illustrates ratio). In summary, the p54nrb promoter
region from 27075 to 27070 bp relative to the ATG protein start
codon is responsible for the MIA/CD-RAP-dependent activation
of the p54nrb promoter during cartilage differentiation.
Identification of the transcription factor that acti-
vates the p54nrb promoter in a MIA/CD-RAP-dependent
fashion. We used the MatInspector analysis to identify the
MIA/CD-RAP-dependent transcription factor mediating the
activation of the p54nrb promoter. In a recent study in melanoma,
we found that YBX1 could transcriptionally regulate MIA/CD-
RAP-dependent p54nrb transcription [15]. Until today, no link
between YBX1 and chondrogenesis has been observed; however,
we aimed to define whether this regulation was also important in
cartilage differentiation. Reporter gene assays using a YBX1
promoter luciferase construct (YBX1Luc) [23] revealed signifi-
cantly lower YBX1 activity in MIA-/- differentiated mMSCs than
in the WT differentiated mMSCs (Figure 4A). To examine this
phenomenon in more detail, a luciferase reporter vector with four
tandem repeats of the Y-box consensus oligo linked to a minimal
promoter was used (YBX1Luc II) [24]. Consistent with the
previous results, we showed a significant reduction in YBX1Luc II
activity in the MIA-/- differentiated mMSCs compared with
differentiated WT mMSCs (Figure 4B). The phosphorylation of
YBX1 at serine 102 (S102) is required for its transcriptional
activity [28]; we therefore analyzed the level of phospho-S102
YBX1 in a panel of differentiated WT and MIA-/- mMSCs
(Figure 4C). P54nrb protein levels served as controls. Together with
the reduced p54nrb protein levels, phospho-S102 YBX1 was
considerably reduced in the MIA-/- mMSCs compared to the WT
mMSCs. Ultimately, we defined YBX1 as the transcriptional
activator of the p54nrb promoter that mediates the regulatory
activity of MIA/CD-RAP in chondrogenesis.
YBX1 in cartilage differentiation
The role of YBX1 in chondrogenic differentiation and in
cartilage in general has not yet been addressed so far. For this
reason, we performed differentiation experiments to determine the
role of YBX1 in this process. We analysed the level of phospho-
S102 YBX1 protein in a panel of undifferentiated and differen-
tiated WT mMSCs. Phospho-S102 YBX1 was elevated in
differentiated WT mMSC compared to undifferentiated cells
(Figure 4D). To reveal the role of YBX1 during cartilage
development in vivo, YBX1 expression was examined in embryonic
cartilage tissue of C57BL/6 wild-type mice by immunostaining
with an antibody raised against YBX1 (Figure 4E). In embryos at
stage 15.5 days post coitum (dpc) scattered, slightly stained
chondrocytes were detectable in the growth plate, whereas at
14.5dpc no YBX1 staining was found. At 16.5dpc, strong YBX1
staining was detected in chondrocytes and in some hypertrophic
chondrocytes of the embryonic growth plate at embryonic stage
16.5dpc (Figure 4E). Immunostaining of adult murine cartilage
tissue revealed intense YBX1 staining in chondrocytes of the
proliferative and hypertrophic chondrocyte zone of the growth
plate and in the bone marrow of SV/129 wild-type mice (Figure 4F
I). No false positive staining was observed due to the detection
system itself (Figure 4F II). These findings are in agreement with
the protein expression of differentiated YBX1 in murine MSCs
(Figure 4C). Further, we detected YBX1 expression in chondro-
cytes of mouse (SV/129 wild-type) and human articular cartilage
(Figure 4F III+IV).
Identification of the conserved sites in genes associated
with cartilage differentiation.
To reveal further downstream effectors that mediate the effect
of MIA/CD-RAP on cartilage differentiation, we screened the
promoter regions of additional genes for the presence of the MIA/
CD-RAP-dependent regulatory sequence found in the p54nrb
promoter. A comprehensive scan of the human genome with the
sequence TTGATTGGCAGT revealed the identities of 175
embryos at different developmental stages. At stage 14.5 days post coitum no YBX1 staining was detected. Scattered and slightly stained
chondrocytes were assessed in ribs of 15.5dpc embryos. At 16.5dpc, strong YBX1 expression was detected in chondrocytes and hypertrophic
chondrocytes. (F) Immunostaining of YBX1 in tibial growth plates revealed its strong expression in chondrocytes of the proliferative and hypertrophic
chondrocyte zone and bone marrow (I). Positive signals were also detected in mouse (II) and human (II) cartilage. The black arrows mark positive
stained cells. RZ: resting chondrocyte zone; PZ: proliferative chondrocyte zone; HZ: hypertrophic chondrocyte zone; TB: trabecular bone.
doi:10.1371/journal.pone.0082166.g004
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sequences in promoter regions of specific genes; these sites are
located within 10 kb upstream of the annotated transcription start
sites. We assumed that at least a subset of these genes is in fact
regulated by MIA/CD-RAP-YBX1 during chondrocyte differen-
tiation and, therefore, should show a strong correlation with
cartilage differentiation and elevated MIA/CD-RAP expression
[4,3,29]. To identify a set of potential YBX1 targets, we used the
transcriptional profiles available at GSE16464. Of the 175 genes
already identified as having an YBX1 binding site, 155 genes were
found on the microarrays. A paired t-test was performed to
identify significantly differentially expressed genes between the
differentiated and undifferentiated chondrocytes (Figure 5A). We
chose one of the differentially expressed genes (Gnas) known to be
involved in chondrocyte differentiation [30] and confirmed the
change in the mRNA expression levels of this gene in MIA/CD-
RAP-negative differentiated mesenchymal stem cells (Figure 5B).
In summary, our results revealed the effects of secreted MIA/
CD-RAP on the putative transcriptional regulation of additional
genes via the YBX1 transcription factor, thereby establishing
important connections between MIA/CD-RAP and new down-
stream effectors in cartilage development. Further, YBX1 was
shown to be important in cartilage development for the first time.
Discussion
MIA/CD-RAP is an important regulator of chondrogenesis;
however, the signaling induced by MIA/CD-RAP, which is a
secreted molecule, remains mostly unknown. We showed previ-
ously that p54nrb acts as a mediator of MIA/CD-RAP action to
promote chondrogenesis in its early stages by modulating
proliferation and differentiation [7]. In this study, we therefore
concentrated on the analysis of p54nrb regulation by MIA/CD-
RAP as a model system to understand MIA/CD-RAP molecular
signaling and to determine its target genes in chondrogenesis.
In agreement with our study in melanoma cells [15], we
revealed that MIA/CD-RAP-dependent modulation of the p54nrb
promoter activity is controlled by a conserved 42 bp DNA
element. It is very interesting that these two different cell types
share this common mechanism of regulation. This can be seen as
proof of conserved regulation following exposure to MIA/CD-
RAP. The importance of YBX1 in the MIA/CD-RAP-dependent
regulatory region of the p54nrb promoter should be confirmed in
the chondrogenic system; however, until now, YBX1 was not
known to play a role in chondrocyte differentiation or in cartilage
development. Consistent with the binding of YBX1 to the
promoter region, we revealed MIA/CD-RAP-dependent activa-
tion of YBX1 by S102 phosphorylation, confirming the activation
of YBX1 in chondrocytes during differentiation. Here, we have
made a major step in understanding the promotion of chondro-
genesis by MIA/CD-RAP via its downstream target p54nrb.
YBX1 expression had not been implicated in chondrocyte
differentiation or cartilage previously. There are some hints in the
literature that YBX1 could be important in cartilage as YBX1-
deficient mice die around the time that cartilage differentiation
begins [21,31]. YBX1 is also known to play a role in insulin signaling,
which is important in cartilage differentiation [32]. However, its role
in cartilage differentiation per se was not addressed in these
publications. Here, we revealed the expression and activity of YBX1
in mMSCs in response to MIA/CD-RAP. Interestingly, immuno-
histochemistry clearly confirmed the impact of YBX1 in cartilage
development. Because this expression pattern is similar to that of
MIA/CD-RAP during cartilage development [4,3], these findings
underline the role of YBX1 as a mediator of MIA/CD-RAP in
chondrocyte differentiation. To further uncover downstream effec-
tors that may mediate the effects of MIA/CD-RAP during
chondrogenesis via the regulation of YBX1, we screened for
potential YBX1 binding sites in the promoters of genes associated
with cartilage differentiation. We identified 62 genes with potential
YBX1 binding sites and coherent expression across differentiated
chondrocytes. The MIA/CD-RAP-dependent regulation of one of
these genes (Gnas) was analyzed as a proof of concept and could be
readily confirmed based on its mRNA levels in mesenchymal stem
cells. Gnas encodes the a subunit (Gsa) of a stimulatory heterotri-
meric G protein (Gs) that transduces signals from various cell-surface
receptors to adenylyl cyclases. Gsa was shown to be the primary
mediator of the actions of the PTH/PTHrP receptor in growth plate
chondrocytes, as Gnas-deficient chondrocytes undergo premature
hypertrophy [30]. Therefore, the activation of YBX1 throughMIA/
CD-RAP is a new aspect in the understanding of how MIA/CD-
RAP fulfills its role in chondrogenesis.
YBX1 activation and nuclear translocation is mainly controlled
by the phosphorylation of S102 on YBX1 via the PI3K/AKT
pathway [33,28]. In a previous study, we showed that in
chondrocytes, ERK signaling is inhibited by MIA/CD-RAP via
its binding to integrin a5, which in turn inhibits its activity [34].
However, in mesenchymal stem cells, the inhibition of ERK
signaling did not lead to the regulation of p54nrb expression at either
the mRNA or the protein level [7]. Hence, the intracellular
signaling pathway that underlies the activation of p54nrb expression
by MIA/CD-RAP and YBX1 remains unclear, as no other MIA/
CD-RAP-regulated signaling pathways have been described to date.
In summary, we showed that the transcription factor YBX1 is
activated by MIA/CD-RAP and is necessary for the activation of the
p54nrb promoter, providing insight into that activity ofMIA/CD-RAP
during chondrogenesis. The discovery of a new, previously unknown
function of YBX1 in cartilage and the identification of its targets
provide new avenues of research to understand how MIA/CD-RAP
fulfills its role in chondrogenic differentiation.
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Figure 5. The YBX1 site is conserved in genes associated with cartilage differentiation. (A) Gene expression differences in the genes with
promoters containing the regulatory region GATTGG, which spans the 27075 to 27070 bp region relative to the ATG in the p54nrb promoter region.
Genes are distributed along the x-axis, and the chondrocytic samples are distributed along the y-axis (GSE16464). Chondrocyte differentiation
correlates with MIA/CD-RAP expression levels [4,3,29]. The relative gene expression levels are color coded to indicate higher (yellow) and lower (blue)
expression levels. The genes are distributed along the y-axis, and the cell data are distributed along the x-axis. (B) The mRNA expression levels of
Gnas measured by qRT-PCR were significantly reduced in different lots of differentiated MIA-/- mMSCs compared with WT mMSCs The values
represent the mean 6 s.d. from five experiments. (*p,0.05).
doi:10.1371/journal.pone.0082166.g005
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